NexEos Bio was founded with a mission of developing novel technologies to identify and treat underlying inflammation in eosinophil-mediated diseases.
We bring a sense of urgency to all we do, knowing patients need better solutions to manage their debilitating diseases.
Illuminating eosinophil-driven inflammation for a brighter tomorrow.
Our lead program NDX-3315 (previously NDX33-0) is a novel, non-invasive imaging agent for the diagnosis, treatment monitoring, and management of Eosinophilic Esophagitis (EoE).
We are passionate about our goal of helping patients to maintain a high quality of life and to slow the progression of eosinophil-related diseases.